{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-020059","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.702404+00:00","generated_at":"2026-06-01T21:29:17.634337+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"bioAffinity Q1 revenue $2.4M record; raises CyPath Lung forecast 35%","bullets":["Q1 2024 revenue $2.4M vs $921 prior-year; net loss $2.1M ($0.21 per share) vs $1.5M ($0.18).","CyPath Lung orders annualized growth 547% in first 4 months vs full-year 2023; April up 21% MoM.","Raised 2024 CyPath Lung sales forecast 35%; PPLS subsidiary revenue forecast $9.2-9.6M (up 23%).","Medicare reimbursement for CyPath Lung effective Jan 1, 2024; adoption expanding beyond Texas.","Closed $2.5M registered direct offering; cash $2.5M at March 31, 2024 vs $2.8M Dec 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-020059","json":"https://secwatch.observer/filing/0001493152-24-020059.json","markdown":"https://secwatch.observer/filing/0001493152-24-020059.md","text":"https://secwatch.observer/filing/0001493152-24-020059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315224020059/0001493152-24-020059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315224020059/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T21:29:17.634337+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dad09d0b663cd6f70f39443d8f4f968242629a8b","claim":"bioAffinity Technologies, Inc. reported the three months ended March 31, 2024 results: revenue $2.4 million, net income $2.1 million, EPS $0.21 per share. Guidance raised.","evidence_excerpt":"First Quarter Financial Results Revenue for the first quarter of 2024 was $2.4 million, compared with $921 revenue for the prior-year period. The majority of the year-over-year increase is through the acquisition of Precision Pathology Laboratory Services. Revenue is primarily generated from patient service fees, including billing for CyPath ® Lung tests, with additional revenues generated from histology service fees and medical director fees. Research and development expenses were $394,000 for the first quarter of 2024, compared with $370,000 for the comparable period in 2023. The increase was primarily due to higher compensation costs for additional research personnel and higher R&D laboratory supply costs. Clinical development expenses were $49,000 for the first quarter of 2024, compared with $20,000 for the first quarter of 2023. The increase was primarily due to an increase in compensation costs and benefits from the addition of new clinical development personnel. Selling, general","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315224020059/0001493152-24-020059-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$2.4 million"},{"label":"Net income","value":"$2.1 million"},{"label":"EPS","value":"$0.21 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}